1-3 of 3
François Hemery
Close
Sort by
Journal Articles

Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: An Economic Analysis.

Michael Schwarzinger, MD, PhD, Celine Beauchamp, PhD, Sebastien Maury, MD PhD, Cecile Pautas, MD, Anne Vekhoff, MD, Hassan Farhat, MD, Felipe Suarez, MD, François Hemery, MD, Mathieu Kuentz, MD, Patrick Maison, MD PhD, Catherine Cordonnier, MD
Journal: Blood
Blood (2006) 108 (11): 2021.
https://doi.org/10.1182/blood.V108.11.2021.2021
Published: 2006
Journal Articles

Early Response Evaluation with 18 FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma.

Jehan Dupuis, Philippe Gaulard, Emmanuel Itti, Alain Rahmouni, François Hemery, Josette Brière, Bettina Fabiani, Christiane Copie-Bergman, Christian Gisselbrecht, Michel Meignan, Félix Reyes, Corinne Haioun
Journal: Blood
Blood (2005) 106 (11): 1914.
https://doi.org/10.1182/blood.V106.11.1914.1914
Published: 2005
Journal Articles

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

Clinical Trials & Observations
Nicole Casadevall, Pierre Durieux, Stéphanie Dubois, François Hemery, Eric Lepage, Marie-Catherine Quarré, Gandhi Damaj, Stéphane Giraudier, Agnès Guerci, Guy Laurent, Hervé Dombret, Christine Chomienne, Vincent Ribrag, Aspasia Stamatoullas, Jean-Pierre Marie, Anne Vekhoff, Frédéric Maloisel, Robert Navarro, François Dreyfus, Pierre Fenaux, for the Groupe Français des Myélodysplasies
Journal: Blood
Blood (2004) 104 (2): 321–327.
https://doi.org/10.1182/blood-2003-07-2252
Published: 2004